search
Back to results

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Primary Purpose

Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
erlotinib hydrochloride
laboratory biomarker analysis
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adult Primary Cholangiocellular Carcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically or cytologically confirmed hepatocellular carcinoma (HCC) or biliary carcinoma that is surgically unresectable; exception: for surgically unresectable HCC, a hypervascular mass on CT and an AFP > 100ng/mL will suffice as noninvasive diagnostic criteria Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as ≥ 2.0 cm Absolute neutrophil count (ANC) ≥ 1500/mm3 PLT ≥ 75,000/mm3 Total bilirubin ≤ 2 x upper normal limits (UNL) Serum AST ≤ 3 x UNL Serum ALT ≤ 3 x UNL Serum creatinine ≤ 2 mg/dL Serum albumin ≥ 2.5 g/dL Patients not receiving anticoagulation: INR ≤ 1.5 ECOG performance status (PS) 0, 1, or 2 Estimated life expectancy ≥ 3 months Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide written informed consent HCC Patients Only: Child-Pugh classification of A or B For patients having prior cryotherapy, radiofrequency ablation, ethanol injection, or photodynamic therapy, the following criteria must be met: > 6 weeks has elapsed since that therapy Indicator lesion(s) is/are outside the area of prior treatment or, if the only indicator lesion is inside the prior treatment area, there must be clear evidence of disease progression associated with that lesion Edges of the indicator lesion are clearly distinct on CT scanning Exclusion Criteria: Ampulla of Vater tumors Any of the following as this regimen may be harmful to a developing fetus or nursing child: Pregnant women Breastfeeding women Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.) NOTE: The effects of OSI-774 on the developing human fetus at the recommended therapeutic dose are unknown Any of the following: > 1 prior systemic anticancer therapy; Note: Chemoembolization will be considered as one prior chemotherapeutic regimen. Prior EGFR targeting therapy Nitrosoureas or mitomycin C ≤6 weeks prior to study entry Other chemotherapy ≤4 weeks prior to study entry • Immunotherapy ≤ 4 weeks prior to study entry Biologic therapy ≤ 4 weeks prior to study entry Radiation therapy ≤ 4 weeks prior to study entry Prior cryotherapy, radiofrequency ablation, ethanol injection or photodynamic therapy ≤6 weeks prior to study entry Failure to fully recover from adverse effects of prior therapies regardless of interval since last treatment Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational Major surgery, or significant traumatic injury occurring ≤ 3 weeks prior to planned treatment start date Any of the following: Gastrointestinal tract disease resulting in an inability to take oral medication Requirement for IV alimentation Prior procedures affecting absorption Active peptic ulcer disease History of other malignancy other than hepatocellular or biliary carcinoma within the previous 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma of the cervix Known abnormalities of the cornea such as: History of dry eye syndrome or Sjorgen's syndrome Congenital abnormality (e.g., Fuch's dystrophy) Abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal-Rose) Abnormal corneal sensitivity test (Schirmer test or similar tear production test) Known CNS metastases; NOTE: These patients are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events Uncontrolled intercurrent illness including, but not limited to: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris, cardiac arrhythmia Psychiatric illness/social situations that would limit compliance with study requirements HIV-positive patients receiving combination anti-retroviral therapy; NOTE: Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; these patients are excluded from the study because of possible pharmacokinetic interactions with OSI-774; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Arm I

Arm Description

Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Proportion of patients who are progression-free at 24 weeks
Confidence intervals for the true PFR will be calculated using the methods of Duffy-Santner.

Secondary Outcome Measures

Objective response, defined by the RECIST criteria in terms of tumor/lesion size and change
Overall survival
The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time to disease progression
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
EGFR protein levels
We will evaluate these EGFR protein levels and explore their association with clinical outcome.
Overall response rate in EGFR positive patients
Analyses will be done independently on patients from each patient group. Corresponding 95% confidence intervals will also be calculated.

Full Information

First Posted
April 9, 2002
Last Updated
June 3, 2013
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00033462
Brief Title
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Official Title
A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
November 2006 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib may interfere with the growth of cancer cells and slow the growth of the tumor.
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with unresectable hepatocellular or biliary carcinoma treated with OSI-774 who are progression-free at 24 weeks. SECONDARY OBJECTIVES: I. To evaluate the toxicity profile of this treatment in each of the patient groups. II. To evaluate the objective response rate of patients with hepatocellular or biliary carcinoma treated with OSI-774. III. To evaluate overall and progression-free survival. IV. To assess the EGFR protein levels and explore their association with clinical outcome. OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups according to cancer type (hepatocellular vs biliary). Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for up to 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
78 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm I
Arm Type
Experimental
Arm Description
Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
erlotinib hydrochloride
Other Intervention Name(s)
CP-358,774, erlotinib, OSI-774
Intervention Description
Given orally
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Proportion of patients who are progression-free at 24 weeks
Description
Confidence intervals for the true PFR will be calculated using the methods of Duffy-Santner.
Time Frame
At 24 weeks
Secondary Outcome Measure Information:
Title
Objective response, defined by the RECIST criteria in terms of tumor/lesion size and change
Time Frame
Up to 3 years
Title
Overall survival
Description
The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time Frame
Time from registration to death due to any cause, assessed up to 3 years
Title
Time to disease progression
Description
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
Time Frame
Time from registration to documentation of disease progression, assessed up to 3 years
Title
EGFR protein levels
Description
We will evaluate these EGFR protein levels and explore their association with clinical outcome.
Time Frame
Baseline
Title
Overall response rate in EGFR positive patients
Description
Analyses will be done independently on patients from each patient group. Corresponding 95% confidence intervals will also be calculated.
Time Frame
Up to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed hepatocellular carcinoma (HCC) or biliary carcinoma that is surgically unresectable; exception: for surgically unresectable HCC, a hypervascular mass on CT and an AFP > 100ng/mL will suffice as noninvasive diagnostic criteria Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as ≥ 2.0 cm Absolute neutrophil count (ANC) ≥ 1500/mm3 PLT ≥ 75,000/mm3 Total bilirubin ≤ 2 x upper normal limits (UNL) Serum AST ≤ 3 x UNL Serum ALT ≤ 3 x UNL Serum creatinine ≤ 2 mg/dL Serum albumin ≥ 2.5 g/dL Patients not receiving anticoagulation: INR ≤ 1.5 ECOG performance status (PS) 0, 1, or 2 Estimated life expectancy ≥ 3 months Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide written informed consent HCC Patients Only: Child-Pugh classification of A or B For patients having prior cryotherapy, radiofrequency ablation, ethanol injection, or photodynamic therapy, the following criteria must be met: > 6 weeks has elapsed since that therapy Indicator lesion(s) is/are outside the area of prior treatment or, if the only indicator lesion is inside the prior treatment area, there must be clear evidence of disease progression associated with that lesion Edges of the indicator lesion are clearly distinct on CT scanning Exclusion Criteria: Ampulla of Vater tumors Any of the following as this regimen may be harmful to a developing fetus or nursing child: Pregnant women Breastfeeding women Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.) NOTE: The effects of OSI-774 on the developing human fetus at the recommended therapeutic dose are unknown Any of the following: > 1 prior systemic anticancer therapy; Note: Chemoembolization will be considered as one prior chemotherapeutic regimen. Prior EGFR targeting therapy Nitrosoureas or mitomycin C ≤6 weeks prior to study entry Other chemotherapy ≤4 weeks prior to study entry • Immunotherapy ≤ 4 weeks prior to study entry Biologic therapy ≤ 4 weeks prior to study entry Radiation therapy ≤ 4 weeks prior to study entry Prior cryotherapy, radiofrequency ablation, ethanol injection or photodynamic therapy ≤6 weeks prior to study entry Failure to fully recover from adverse effects of prior therapies regardless of interval since last treatment Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational Major surgery, or significant traumatic injury occurring ≤ 3 weeks prior to planned treatment start date Any of the following: Gastrointestinal tract disease resulting in an inability to take oral medication Requirement for IV alimentation Prior procedures affecting absorption Active peptic ulcer disease History of other malignancy other than hepatocellular or biliary carcinoma within the previous 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma of the cervix Known abnormalities of the cornea such as: History of dry eye syndrome or Sjorgen's syndrome Congenital abnormality (e.g., Fuch's dystrophy) Abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal-Rose) Abnormal corneal sensitivity test (Schirmer test or similar tear production test) Known CNS metastases; NOTE: These patients are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events Uncontrolled intercurrent illness including, but not limited to: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris, cardiac arrhythmia Psychiatric illness/social situations that would limit compliance with study requirements HIV-positive patients receiving combination anti-retroviral therapy; NOTE: Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; these patients are excluded from the study because of possible pharmacokinetic interactions with OSI-774; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Philip
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

We'll reach out to this number within 24 hrs